MAT Biopharma is a private biotech company founded in 1999, specialising in the development of antibody-based therapeutics for the treatment of cancer. The Company has a focused portfolio of products in development, including one product currently in phase I/II and five at different stages of preclinical development.
MAT Biopharma 's products target tumours via several different mechanisms and are being developed to treat a range of haematological and solid cancers, including pancreatic and liver cancers.